REDWOOD CITY, Calif., June 4 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. , today announced that the Company will make a presentation at the American Society of Clinical Oncology (ASCO) meeting being held at McCormick Place in Chicago. Charles Hart, Ph.D., Senior Director of Biology, will be presenting at the conference on June 5th at 11:15am Central Time in a clinical science symposium entitled: “Targeting Tumor Hypoxia”.
To access the abstract: Go to the Event Calendar section of the Company’s website (http://investor.thresholdpharm.com/calendar.cfm) and click on Additional Information under the American Society of Clinical Oncology header.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company’s drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (http://www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold’s product candidates, clinical trial progress and results, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold’s ability to complete its anticipated clinical trials, the time and expense required to conduct such clinical trials, and the results of such clinical trials (including unanticipated product safety issues as well as efficacy results). Further information regarding these and other risks is included under the heading “Risk Factors” in Threshold’s Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 9, 2007 and is available from the SEC’s website (http://www.sec.gov) and on our website (http://www.thresholdpharm.com) under the heading “Investors.” We undertake no duty to update any forward-looking statement made in this news release.
Contact: Denise T. Powell Sr. Director, Corporate Communications Threshold Pharmaceuticals, Inc. 650-474-8206 dpowell@thresholdpharm.com
Threshold Pharmaceuticals, Inc.
CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206,dpowell@thresholdpharm.com
Web site: http://www.thresholdpharm.com/
